Porphyria treatment of all forms of porphyria involves addressing the underlying genetic defect and ensuring that the affected area of the liver is treated effectively so as to prevent further skin damage. Porphyria is a very rare genetic disorder that attacks the nervous system of the skin and can cause severe abdominal pain. Cells of patients suffering from porphyria are unable to alter the chemicals of the body known as porphyrins. The various forms that impact the central nervous system are sometimes called acute porphyria, due to the quick onset and brief duration of symptoms. Severe porphyria is characterized by chronic wasting syndrome (CMS) where the skin begins to thicken and eventually becomes leathery.
The main factor influencing the porphyria treatment market is the increase in the number of cases of porphyria. Even though the prevalence of the disease is still not clear to experts, the probability ranges from 1 in 500 to 1 in 50,000 individuals across the globe. For instance, according to the U.S. National Center for Biotechnology Information, porphyria is a very rare disease affecting less than 200,000 individuals. Acute porphyria occurs frequently in regions such as the U.K., Sweden, and Northern Europe. Growth in investments related to R&D sectors for the development of better treatment options is expected to propel the growth of the porphyria treatment market. Additionally, government initiative especially in emerging economies and expansion of health care sectors is expected to augment the market growth.
However, less knowledge and uncertainty of the disease are the main restraining factor hindering the market growth of porphyria treatment.
This market is distributed in five regions that include North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these North America and Europe jointly is estimated to hold a significant share of the porphyria treatment market owing to the presence of key industry players introducing new products and initiating R&D processes for better product development. The spread of healthcare sectors in these regions is also expected to drive the growth of the porphyria treatment market. For instance, according to the U.S. National Institutes of Health, Porphyria cutanea tarda (PCT) is a very prevalent disease in the U.K. affecting 1 in every 10,000 people or 2 in every 5 million individuals in the region. The porphyria treatment market in the Asia Pacific is estimated to witness significant incidence owing to the growth in awareness related to porphyria and the extensive patient population. Additionally, favorable government initiatives to support the healthcare infrastructure are expected to propel the growth of the porphyria treatment market in the region.
Key players operating in the porphyria treatment market include Bio-Rad Laboratories, Inc., ACON Laboratories, Inc., Dahaner, Siemens AG, Hoffmann-La Roche Ltd, Sysmex Corporation and ARKRAY, Inc.
In November 2019, the U.S. Food and Drug Administration approved GIVLAARI injection for treating adults suffering from acute hepatic porphyria (AHP).
No comments:
Post a Comment